Close Menu

NEW YORK – A new study spelling out the range of mutations that can arise in colorectal cancer (CRC) in response to targeted treatments suggests that the tumors increase their mutation rate to become resistant.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.